Payment overview · 2025
General Payments
$543.28
20 reported records · 9 companies
Healthcare provider profile · identity verified
Rafael Soto, M.D.
Allopathic & Osteopathic Physicians|General Practice · TOA BAJA, PR · NPI 1932105665
Verified facts
What the public records show
CMS Open Payments records show Rafael Soto, M.D. received $543.28 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Lokelma, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 1079 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synjardy by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 342 records involving 186 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 147 records involving 126 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $269.03 | 49.5% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.14 | 10.5% | 2 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $47.86 | 8.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.24 | 7.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.13 | 5.2% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $25.00 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.00 | 4.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.00 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.88 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.28 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $195.70 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $140.93 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.14 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $47.86 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 271 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
1079 | 260 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
271 | 71 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 342 supporting records · 186 recipient NPIs · example record 1186464879 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 46 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 147 supporting records · 126 recipient NPIs · example record 1228798592 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
68 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1510 | 373 |
| Losartan Potassium | Losartan Potassium | 1213 | 336 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1187 | 346 |
| Synthroid | Levothyroxine Sodium | 1079 | 260 |
| Simvastatin | Simvastatin | 1005 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 992 | 291 |
| Pantoprazole Sodium | Pantoprazole Sodium | 982 | 235 |
| Metformin Hcl | Metformin Hcl | 914 | 262 |
| Famotidine | Famotidine | 811 | 198 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 808 | 264 |
| Metoprolol Succinate | Metoprolol Succinate | 795 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 760 | 206 |
| Montelukast Sodium | Montelukast Sodium | 628 | 230 |
| Hydrochlorothiazide | Hydrochlorothiazide | 613 | 179 |
| Omeprazole | Omeprazole | 608 | 140 |
| Diclofenac Sodium | Diclofenac Sodium | 566 | 140 |
| Clonazepam | Clonazepam | 545 | 99 |
| Diclofenac Potassium | Diclofenac Potassium | 494 | 149 |
| Lisinopril | Lisinopril | 490 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 477 | 137 |
| Alendronate Sodium | Alendronate Sodium | 468 | 115 |
| Dexamethasone | Dexamethasone | 457 | 271 |
| Glimepiride | Glimepiride | 452 | 134 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 451 | 139 |
| Levofloxacin | Levofloxacin | 385 | 300 |
| Clopidogrel | Clopidogrel Bisulfate | 375 | 114 |
| Donepezil Hcl | Donepezil Hcl | 347 | 84 |
| Tizanidine Hcl | Tizanidine Hcl | 341 | 109 |
| Temazepam | Temazepam | 328 | 65 |
| Pentoxifylline | Pentoxifylline | 318 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 76 |
| Furosemide | Furosemide | 301 | 90 |
| Azithromycin | Azithromycin | 276 | 220 |
| Farxiga | Dapagliflozin Propanediol | 271 | 71 |
| Candesartan Cilexetil | Candesartan Cilexetil | 266 | 70 |
| Meloxicam | Meloxicam | 262 | 81 |
| Trazodone Hcl | Trazodone Hcl | 243 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 240 | 70 |
| Ezetimibe | Ezetimibe | 224 | 77 |
| Dicyclomine Hcl | Dicyclomine Hcl | 220 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 219 | 59 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 212 | 43 |
| Sucralfate | Sucralfate | 211 | 60 |
| Sertraline Hcl | Sertraline Hcl | 210 | 53 |
| Jardiance | Empagliflozin | 207 | 54 |
| Irbesartan | Irbesartan | 205 | 61 |
| Trulicity | Dulaglutide | 195 | 24 |
| Eliquis | Apixaban | 190 | 46 |
| Memantine Hcl | Memantine Hcl | 189 | 48 |
| Enalapril Maleate | Enalapril Maleate | 183 | 45 |
| Finasteride | Finasteride | 181 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 31 |
| Meclizine Hcl | Meclizine Hcl | 177 | 67 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 171 | 47 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 167 | 52 |
| Baclofen | Baclofen | 159 | 70 |
| Lorazepam | Lorazepam | 159 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 157 | 78 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 31 |
| Glipizide Er | Glipizide | 142 | 46 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 139 | 33 |
| Alprazolam | Alprazolam | 137 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 21 |
| Glipizide | Glipizide | 135 | 38 |
| Xarelto | Rivaroxaban | 132 | 33 |
| Mupirocin | Mupirocin | 131 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 27 |
| Nabumetone | Nabumetone | 127 | 35 |
| Carvedilol | Carvedilol | 121 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 118 | 34 |
| Sildenafil Citrate | Sildenafil Citrate | 116 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 115 | 34 |
| Lidocaine | Lidocaine | 115 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 115 | 97 |
| Allopurinol | Allopurinol | 114 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 94 |
| Doxazosin Mesylate | Doxazosin Mesylate | 112 | 38 |
| Fenofibrate | Fenofibrate | 110 | 32 |
| Latanoprost | Latanoprost | 110 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 108 | 33 |
| Methylprednisolone | Methylprednisolone | 108 | 75 |
| Metoclopramide Hcl | Metoclopramide Hcl | 101 | 35 |
| Tradjenta | Linagliptin | 101 | 27 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 100 | 29 |
| Cilostazol | Cilostazol | 100 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 29 |
| Azelastine Hcl | Azelastine Hcl | 99 | 35 |
| Ozempic | Semaglutide | 99 | 23 |
| Etodolac | Etodolac | 98 | 28 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 19 |
| Pregabalin | Pregabalin | 94 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 93 | 33 |
| Prednisone | Prednisone | 90 | 21 |
| Ramipril | Ramipril | 90 | 23 |
| Betamethasone Valerate | Betamethasone Valerate | 88 | 23 |
| Ibuprofen | Ibuprofen | 87 | 31 |
| Albuterol Sulfate | Albuterol Sulfate | 86 | 54 |
| Spironolactone | Spironolactone | 84 | 27 |
| Ketoconazole | Ketoconazole | 83 | 18 |
| Nifedipine Er | Nifedipine | 81 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 26 |
| Humalog | Insulin Lispro | 79 | 17 |
| Lansoprazole | Lansoprazole | 79 | 16 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 76 | 28 |
| Valsartan | Valsartan | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 23 |
| Risperidone | Risperidone | 73 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 26 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 72 | 45 |
| Folic Acid | Folic Acid | 71 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 69 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 69 | 59 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 17 |
| Mometasone Furoate | Mometasone Furoate | 69 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 68 | 67 |
| Atenolol | Atenolol | 66 | 20 |
| Buspirone Hcl | Buspirone Hcl | 66 | 14 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 65 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 62 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 17 |
| Ciclopirox | Ciclopirox | 58 | 29 |
| Synjardy | Empagliflozin/Metformin Hcl | 58 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 16 |
| Levetiracetam | Levetiracetam | 57 | 14 |
| Mirtazapine | Mirtazapine | 57 | 14 |
| Naproxen | Naproxen | 57 | 12 |
| Lumigan | Bimatoprost | 55 | 14 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 55 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 12 |
| Ciclopirox | Ciclopirox Olamine | 52 | 25 |
| Sulindac | Sulindac | 52 | 22 |
| Fluconazole | Fluconazole | 51 | 32 |
| Olanzapine | Olanzapine | 51 | 18 |
| Telmisartan | Telmisartan | 51 | 15 |
| Verapamil Er | Verapamil Hcl | 51 | 17 |
| Halobetasol Propionate | Halobetasol Propionate | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 11 |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 48 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Metformin Hcl Er | Metformin Hcl | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 48 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 48 | 14 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | 13 |
| Rivastigmine | Rivastigmine | 47 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 46 | 13 |
| Anastrozole | Anastrozole | 45 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 16 |
| Insulin Lispro | Insulin Lispro | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Linzess | Linaclotide | 44 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | 13 |
| Acyclovir | Acyclovir | 43 | 32 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 43 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 43 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 40 | suppressed |
| Fluorometholone | Fluorometholone | 40 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 13 |
| Lamotrigine | Lamotrigine | 38 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | 20 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 16 |
| Glyxambi | Empagliflozin/Linagliptin | 36 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 34 | 12 |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 33 | 14 |
| Atrovent Hfa | Ipratropium Bromide | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Estazolam | Estazolam | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Glipizide Xl | Glipizide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Humulin N | Insulin Nph Human Isophane | 30 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 11 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Ssd | Silver Sulfadiazine | 29 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Enulose | Lactulose | 28 | 11 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 26 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 25 | 14 |
| Lactulose | Lactulose | 25 | 13 |
| Calcitriol | Calcitriol | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Orphenadrine Citrate | Orphenadrine Citrate | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Desonide | Desonide | 22 | suppressed |
| Ivermectin | Ivermectin | 22 | 15 |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Cimetidine | Cimetidine | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Brilinta | Ticagrelor | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Travoprost | Travoprost | 18 | suppressed |
| Benzonatate | Benzonatate | 17 | 11 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | 11 |
| Galantamine Hbr | Galantamine Hbr | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Permethrin | Permethrin | 14 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $543.28 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, JARDIANCE, LOKELMA, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error